Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
542
datasets available to search
ShareScore release 0.9.0
Dataset results
542 results for “HIV prevention”
HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV
ClinicalTrials.gov study NCT00442962. IPD Sharing: Not stated. Countries: 3. Publications: 3.
A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infect
ClinicalTrials.gov study NCT03060629. IPD Sharing: Not stated. Countries: 5. Publications: 3.
Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men
ClinicalTrials.gov study NCT00458393. IPD Sharing: Not stated. Countries: 6. Publications: 13.
NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission
ClinicalTrials.gov study NCT00089505. IPD Sharing: Not stated. Countries: 7. Publications: 14.
Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)
ClinicalTrials.gov study NCT04686279. IPD Sharing: NO. Countries: 1. Publications: 2.
Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
ClinicalTrials.gov study NCT01461096. IPD Sharing: Not stated. Countries: 3. Publications: 4.
ARVs to Prevent Breastmilk HIV:Viral and Immune Responses
ClinicalTrials.gov study NCT00167674. IPD Sharing: UNDECIDED. Countries: 1. Publications: 5.
Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
ClinicalTrials.gov study NCT02968849. IPD Sharing: NO. Countries: 1. Publications: 6.
Integrated Care Delivery of HIV Prevention and Treatment in AGYW in Zambia
ClinicalTrials.gov study NCT03995953. IPD Sharing: YES. Countries: 1. Publications: 3.
Data from: Implementation of Option B and a fixed-dose combination antiretroviral regimen for prevention of mother-to-child transmission of HIV in South Africa: a model of uptake and adherence to care
Open the record for dataset details and reuse information.
SAFER: Safer conception strategies to prevent HIV transmission among HIV sero-different couples desiring pregnancy
Open the record for dataset details and reuse information.
Data from: Optimizing prevention of HIV mother to child transmission: duration of antiretroviral therapy and viral suppression at delivery among pregnant Malawian women
Background: Effective antiretroviral therapy during pregnancy minimizes the risk of vertical HIV transmission. Some women present late in their pregnancy for first antenatal visit; whether these women achieve viral suppression by delivery and how suppression varies with time on ART is unclear. Methods: We conducted a prospective cohort study of HIV-infected pregnant women initiating antiretroviral therapy for the first time from June 2015 to November 2016. Multivariable Poisson models with robust variance estimators were used to estimate risk ratios (RR) and 95% confidence intervals (CI) of the association between duration of ART and both viral load (VL) ≥1000 copies/ml and VL ≥40 copies/ml at delivery. Results: Of the 252 women who had viral load testing at delivery, 40 (16%) and 78 (31%) had VL ≥1000 copies/ml and VL ≥40 copies/ml, respectively. The proportion of women with poor adherence to ART was higher among women who were on ART for ≤12 weeks (9/50 = 18.0%) than among those who were on ART for 13-35 weeks (18/194 = 9.3%). Compared to women who were on ART for ≤12 weeks, women who were on ART for 13-20 weeks (RR = 0.52; 95% CI: 0.36-0.74) or 21-35 weeks (RR = 0.26; 95% CI: 0.14-0.48) had a lower risk of VL ≥40 copies/ml at delivery. Similar comparisons for VL ≥1000 copies/ml at delivery showed decrease in risk although not significant for those on ART 13-20 weeks. Conclusion: Longer duration of ART during pregnancy was associated with suppressed viral load at delivery. Early ANC attendance in pregnancy to facilitate prompt ART initiation for HIV-positive women is essential in the effort to eliminate HIV vertical transmission.
Data from: How can we get close to zero?: the potential contribution of biomedical prevention and the investment framework towards an effective response to HIV
Background: In 2011 an Investment Framework was proposed that described how the scale-up of key HIV interventions could dramatically reduce new HIV infections and deaths in low and middle income countries by 2015. This framework included ambitious coverage goals for prevention and treatment services resulting in a reduction of new HIV infections by more than half. However, it also estimated a leveling in the number of new infections at about 1 million annually after 2015. Methods: We modeled how the response to AIDS can be further expanded by scaling up antiretroviral treatment (ART) within the framework provided by the 2013 WHO treatment guidelines. We further explored the potential contributions of new prevention technologies: 'Test and Treat', pre-exposure prophylaxis and an HIV vaccine. Findings: Immediate aggressive scale up of existing approaches including the 2013 WHO guidelines could reduce new infections by 80%. A 'Test and Treat' approach could further reduce new infections. This could be further enhanced by a future highly effective pre-exposure prophylaxis and an HIV vaccine, so that a combination of all four approaches could reduce new infections to as low as 80,000 per year by 2050 and annual AIDS deaths to 260,000. Interpretation: In a set of ambitious scenarios, we find that immediate implementation of the 2013 WHO antiretroviral therapy guidelines could reduce new HIV infections by 80%. Further reductions may be achieved by moving to a 'Test and Treat' approach, and eventually by adding a highly effective pre-exposure prophylaxis and an HIV vaccine, if they become available.
Figure 2 in Placebo-Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV-1 Infection
Figure 2. Self-reported risk behaviors by treatment arm and month of visit. STDs, sexually transmitted diseases.
A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
ClinicalTrials.gov study NCT00004579. IPD Sharing: Not stated. Countries: 1. Publications: 1.
An Assessment of an HIV Prevention Intervention (Project AIM) Among Junior Secondary School Students in Eastern Botswana
ClinicalTrials.gov study NCT02455583. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Male Involvement in Antenatal Care and the Prevention Programme of Mother-to-child Transmission of HIV in Uganda
ClinicalTrials.gov study NCT01144234. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Assessing the Impact of an Intervention to Prevent Intimate Partner Violence and HIV in Uganda
ClinicalTrials.gov study NCT02050763. IPD Sharing: Not stated. Countries: 1. Publications: 4.
HOPE (Harnessing Online Peer Education): Using Online Social Networks for HIV Prevention and Testing
ClinicalTrials.gov study NCT01701206. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Improving Uptake of Early Infant Diagnosis of HIV for the Prevention of Mother-to-child Transmission of HIV
ClinicalTrials.gov study NCT01433185. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.